Further Solidifies Pivot's Ready-to-Infuse Cannabis Powderization Technology Portfolio
VANCOUVER, Nov. 19, 2018 /CNW/ - Pivot Pharmaceuticals Inc. (CSE: PVOT / OTCQB: PVOTF / FRA: NPAT) ("Pivot" or the "Company") is pleased to announce that its wholly-owned subsidiary, Pivot Naturals LLC, has received three more Notices of Allowance from the U.S. Patent and Trademark Office ("USPTO") for patent applications related to its RTIC "Ready-To-Infuse Cannabis" powderization technology. As a result, Pivot Naturals has now been awarded a total of four patents in the RTIC patent family, furthering the scope of protection around the RTIC process and products. The newly allowed patents will also strengthen Pivot's ability to monetize its portfolio of cannabis-related intellectual property.
- Pivot Naturals LLC granted three additional Notices of Allowance from USPTO;
- Patents further strengthen RTIC "Ready-to-Infuse-Cannabis" powderization technology platform;
- RTIC will allow for the manufacturing of unlimited types of products in the edibles market;
- RTIC powder enables accurate and repeatable dosing of THC and/or CBD in beverages, capsules, edibles, stick packs and tablets etc.
RTIC is a ground breaking and disruptive cannabis infusion process that raises the bar for the consistency, accuracy and reliability of manufactured cannabis-infused ingestible products. In addition, the RTIC process solves the challenges of accurate and repeatable dosing that are faced by manufacturers of traditional cannabis oil-based products.
Pivot Naturals' President, Patrick Rolfes, commented: "We are thrilled to receive these three additional patents which provide broader patent protection of our RTIC infusion technology. Pivot strives to be synonymous with the production of safe, reliable and effective cannabis-infused edible products and the RTIC technology is the foundation of achieving that goal. Pivot is also proud to be a part of blazing the trail for other cannabis inventors to protect their inventions with patents, and to help bring further innovation and legitimacy to this burgeoning new industry."
About Pivot Pharmaceuticals Inc.
Pivot Pharmaceuticals Inc. is a biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals using innovative drug delivery platform technologies. Pivot's wholly-owned medical cannabis products division, Pivot Green Stream Health Solutions Inc. ("PGS" or "Pivot Green Stream"), conducts research, development and commercialization of cannabinoid-based nutraceuticals and pharmaceuticals. Pivot's wholly-owned U.S. subsidiary, Pivot Naturals, LLC, based in Costa Mesa, California, will manufacture and supply finished powderized cannabis products such as food additives, capsules, bulk powder and stick packs to the California market. PGS has acquired "RTIC" Ready-To-Infuse Cannabis oil-to-powder technology and Thrudermic Transdermal Nanotechnology (transdermal); acquired worldwide rights to BiPhasix™ Dermal Drug Delivery platform technology (topical), Solmic Solubilisation technology (oral), and Solumer™ Oral Drug Delivery technology; and an option to acquire worldwide rights to TriVair™ Nasal and Pulmonary Breath-Propelled Drug Delivery Systems™ for the delivery and commercialization of cannabinoid, cannabidiol (CBD), and tetrahydrocannabinol (THC)-based products. For more information please visit www.PivotPharma.com
Cautionary Note Regarding Forward-Looking Statements
Except for historical information contained herein, the matters set forth above may be forward-looking statements that involve certain risks and uncertainties that could cause actual results to differ from those in the forward-looking statements. Words such as anticipate, believe, estimate, expect, intend, and similar expressions, as they relate to Pivot Pharmaceuticals Inc., Pivot Green Stream Health Solutions Inc., Pivot Naturals, LLC, or its management, identify forward-looking statements. Such forward-looking statements are based on the current beliefs of management, as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, such as the failure to meet the conditions imposed by the CSE or other securities regulators, the level of business and consumer spending, the amount of sales of Pivot's products, statements with respect to internal expectations, the competitive environment within the industry, the ability of Pivot to continue to expand its operations, the level of costs incurred in connection with Pivot's expansion efforts, economic conditions in the industry, and the financial strength of Pivot's customers and suppliers. Pivot does not undertake any obligation to update such forward-looking statements. Investors are also directed to consider all other risks and uncertainties.
SOURCE Pivot Pharmaceuticals Inc.
For further information: Pivot Pharmaceuticals Inc., Patrick Frankham, PhD, MBA, Chief Executive Officer, Email: Info@PivotPharma.com; Virtus Advisory Group, Shareholder Inquiries, Email: Pivot@virtusadvisory.com, Phone: 416-644-5081